MedTrace Logo

Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy

NCT02714049 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-06-13

No results posted yet for this study

Summary

Unblinded study of flibanserin for 8 weeks with responders randomized 1:1 to receive study medication alone vs. study medication and sex therapy for 12 additional weeks.

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

BEHAVIORAL

sex therapy

60 minutes each time, in person or on the telephone

DRUG

flibanserin

FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women

Sponsors & Collaborators

  • San Diego Sexual Medicine

    lead OTHER

Principal Investigators

  • Irwin Goldstein, MD · San Diego Sexual Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-25
Primary Completion
2019-01-18
Completion
2019-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02714049 on ClinicalTrials.gov